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The World Health Organization has identified India as a major hot-spot region for Mycobacterium tubercu-
losis infection. We have characterized the sequences of the loci associated with multidrug resistance in 126
clinical isolates of M. tuberculosis from India to identify the respective mutations. The loci selected were rpoB
(rifampin), katG and the ribosomal binding site of inhA (isoniazid), gyrA and gyrB (ofloxacin), and rpsL and
rrs (streptomycin). We found known as well as novel mutations at these loci. Few of the mutations at the rpoB
locus could be correlated with the drug resistance levels exhibited by the M. tuberculosis isolates and occurred
with frequencies different from those reported earlier. Missense mutations at codons 526 to 531 seemed to be
crucial in conferring a high degree of resistance to rifampin. We identified a common Arg463Leu substitution
in the katG locus and certain novel insertions and deletions. Mutations were also mapped in the ribosomal
binding site of the inhA gene. A Ser95Thr substitution in the gyrA locus was the most common mutation
observed in ofloxacin-resistant isolates. A few isolates showed other mutations in this locus. Seven strepto-
mycin-resistant isolates had a silent mutation at the lysine residue at position 121. While certain mutations are
widely present, pointing to the magnitude of the polymorphisms at these loci, others are not common,
suggesting diversity in the multidrug-resistant M. tuberculosis strains prevalent in this region. Our results
additionally have implications for the development of methods for multidrug resistance detection and are also
relevant in the shaping of future clinical treatment regimens and drug design strategies.
Recent years have witnessed a dramatic upsurge in cases of
drug-resistant Mycobacterium tuberculosis infections. The ac-
quisition of resistance by the bacterium is a random event, and
in a given mycobacterial population, 1 in 106 bacteria mutates
to develop isoniazid resistance, while 1 in 108 mutates to de-
velop rifampin resistance (8). The chance that a bacterium will
acquire multidrug resistance (defined as resistance to at least
rifampin and isoniazid) is thus 1014 (8). The drug-resistant
phenotype may get selected due to single-drug therapy, poor
patient adherence, and improper diagnosis. With the AIDS
pandemic fuelling increasing numbers of multidrug-resistant
(MDR) strains of M. tuberculosis, urgent measures need to be
taken to contain this scourge (2). A recently published World
Health Organization report reviewing the global status of tu-
berculosis has pointed to an increasing incidence of drug-
resistant tuberculosis (5). The highest rates of MDR tubercu-
losis have been reported in Nepal (48.0%), Gujarat, India
(33.8%), New York City (30.1%), Bolivia (15.3%), and Korea
(14.5%). Furthermore, the report points to the alarming in-
crease in the number of tuberculosis patients in the Indian
subcontinent, with India being singled out as having the great-
est burden of tuberculosis patients. Three different studies
from North and Northwest India indicate an increasing inci-
dence of acquired MDR tuberculosis (9, 12, 15). Furthermore,
the incidence of primary MDR tuberculosis in North India was
put at 3.3% in one of the studies (12).
While there is lot of literature on the molecular epidemiol-
ogy and characterization of MDR isolates from the United
States and Europe, the same is not true for the Indian strains.
The prevalence of drug-resistant tuberculosis in North India is
known, but no serious efforts have been made to identify the
drug resistance genotypes or their prevalence in the commu-
nity. The present study was undertaken to characterize muta-
tions prevalent in patient isolates of M. tuberculosis from North
India with respect to a few of these drug target loci. We have
chosen to look at the drug target genes for the drugs rifampin,
isoniazid, streptomycin, and fluoroquinolones, which are com-
monly prescribed for the treatment of tuberculosis in North
India. The first three drugs are the frontline drugs in tubercu-
losis chemotherapy, while fluoroquinolones are prescribed for
drug-resistant cases. The loci studied were rpoB (RNA poly-
merase B subunit), katG (catalase-peroxidase), inhA (enoyl
coenzyme A reductase), rpsL (ribosomal protein S12), rrs (16S
rRNA), and gyrAB (DNA gyrases A and B). The present study,
in combination with the molecular epidemiology of the drug-
resistant strains, will help track the routes of infection and the
extent of drug-resistant tuberculosis in this region. The eluci-
dation of common and novel mutations in these loci could
form the basis for the creation of new diagnostic tools and the
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development of novel strategies that can be used to combat the
menace of drug-resistant M. tuberculosis.
MATERIALS AND METHODS
Sources of Mycobacterium isolates. Mycobacterium isolates were collected from
patients reporting to the outpatient departments of hospitals in northern India,
primarily New Delhi and its neighboring regions. Another source of samples was
the National Mycobacterial Repository at the Central Jalma Institute for Lep-
rosy, Agra, India. The samples collected over a 3-year period from 1995 to 1998
were included in the present study. A large number of the patients (75%) had
histories of previous treatment and were on antitubercular treatment at the time
of collection of their sputa. Most of these patients had been through various
degrees of antitubercular drug therapy during the previous 20 months. Rifampin
and isoniazid were the most common drugs used in these regimens. Sputum
samples collected from patients reporting with pulmonary tuberculosis were
processed by standard methods and were streaked onto Lowenstein-Jensen
slants. Most of them were coded with ICC numbers (ICC01, ICC201, etc.). The
samples were biochemically characterized as belonging to the M. tuberculosis
complex by nitrate reduction, niacin production, and BACTEC NAP tests. Drug
susceptibility profiles were evaluated by the proportion method. The drugs tested
were rifampin (Lupin, India), isoniazid (Lupin), ofloxacin (Ranbaxy, India), and
streptomycin (Lupin). The MICs at which the isolates were considered resistant
were as follows: 10 g/ml for rifampin, 1 g/ml for isoniazid, 2 g/ml for
ofloxacin, and 2 g/ml for streptomycin. The numbers of drug-resistant isolates
included in the study were as follows: for rifampin, n  94; for isoniazid, n  74;
for streptomycin, n  14; and for ofloxacin, n  68. A total of 126 isolates were
tested. Thirty-six isolates were resistant to a single drug, 66 isolates were resistant
to two drugs, 22 isolates were resistant to three drugs, and 4 isolates were
resistant to four drugs.
DNA isolation and PCR. The isolates were cultured on Lowenstein-Jensen
slants. The colonies were scraped, resuspended in 500 l of TE (10 mM Tris, 1
mM EDTA [pH 8]), and killed by freezing at 70°C followed by heating at 80°C.
This cycle was repeated thrice to kill all the bacteria. The DNA was isolated (by
tretament with cetyltrimethylammonium bromide in the presence of 0.7 M so-
dium chloride) and amplified by standardized protocols as reported previously
(21).
Table 1 lists the sequences of the different primers used and their positions on
the corresponding genes. It also lists the amplicon sizes generated and the
annealing temperatures used for PCR cycling. The temperatures used for all
cycles were identical for all PCRs except for that for annealing, the temperature
of which varied for each primer pair. Briefly, 35 cycles of 94°C for 1 min, 45 to
60°C for 1 min, and 72°C for 2 min were used to amplify the loci. The samples
were resolved in a 2% agarose gel, and the specific bands were excised. DNA was
extracted from the gel slices with a QIAquick gel extraction kit (Qiagen, Chats-
worth, Calif.) according to the manufacturer’s instructions. The purified DNA
was resuspended in sterile double-distilled water and was used for the sequencing
studies.
DNA sequencing. Sequencing of the amplicons was carried out with an ABI
Prism 377 automated DNA sequencer (ABI Prism). PCR sequencing was carried
out with a BigDye terminator kit (ABI Prism) according to the manufacturer’s
instructions. The Sequencing Analysis (version 3.3) software package was used to
analyze the gel information. The sequences generated with the program were
compared to their respective wild-type sequences by using MegAlign software
(Lasergene; DNASTAR, Inc., Madison, Wis.).
RESULTS
Mutations in the hot-spot regions of various loci were char-
acterized. The results are summarized in Table 2. On the basis
of the drug susceptibility profile for an isolate, the correspond-
ing loci (representing the drug target gene) were amplified and
sequenced. The largest number of samples was obtained from
New Delhi, followed by Chandigarh, Ahmedabad, Agra, Ban-
galore, and Shimla, with a few samples coming from Jaipur and
Chennai. Except for Chennai and Bangalore, all the cities are
located in North India. We could establish a previous treat-
ment history for patients from whom 94 of the 126 isolates
TABLE 1. Primers used in the study to amplify and sequence the different loci, amplicon sizes, annealing temperatures,
and amplicon positions on the respective genes
Gene
(accession no.) Primer Sequence
Annealing
temp (°C)
Position
(nt)
Amplicon size
(bp)
rpoB (L27989) Forward GGG AGC GGA TGA CCA CCC 60 2266 350
Reverse GCG GTA CGG CGT TTC GAT GAA C 2615
katG (X68081) Forward GCC CGA GCA ACA CCC 60 3 237
Reverse ATG TCC CGC GTC AGG 239
Forward CGA GGA ATT GGC CGA CGA GTT 55 1187 414
Reverse CGG CGC CGC GGA GTT GAA TGA 1600
inhA regulator sequence Forward CCT CGC TGC CCA GAA AGG GA 45 Upstream of inhA gene 248
Reverse ATC CCC CGG TTT CCT CCG GT
gyrA (L27512) Forward CAG CTA CAT CGA CTA TGC GA 45 2383 320
Reverse GGG CTT CGG TGT TAC CTC AT 2702
gyrB (L27512) Forward CCA CCG ACA TCG GTG GAT T 55 1538 428
Reverse CTG CCA CTT GAG TTT GTA CA 1965
rpsl (X70995) Forward GGC CGA CAA ACA GAA CGT 54 5 noncoding region 505
Reverse GTT CAC CAA CTG GGT GAC S7 gene
rrs (Z83862) Forward TTG GCC ATG CTC TTG ATG CCC 54 141 1140
Reverse TGC ACA CAG GCC ACA AGG GA 1280
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TABLE 2. Characteristics of M. tuberculosis isolates from patients
Strain no. Geographiclocation
Treatment
historya
Drug
susceptibilityb
Polymorphismc
rpo katG or inhA gyrA rpsL
ICC14 New Delhi  Rr, Ir, Or D516V N35D, NA at second locus S95T
ICC19 New Delhi  Rr, Ir, Or L511L, S531L R463L S95T
ICC23 New Delhi  Rr, Ir L511L, S531L NA
ICC98 New Delhi  Ir, Or R463L, Inh (C/T) S95T
ICC100 New Delhi  Rr, Ir, Or, Sr S531L R463L S95T NM
ICC101 New Delhi  Rr, Or S531L S95T
ICC102 New Delhi  Rr, Ir, Or S531L NM S95T
ICC103 New Delhi  Rr, Ir, Or L511L, N518T NM A90A, S95T
ICC104 New Delhi  Rr, Ir, Or D516V 30C, R463L S95T
ICC105 New Delhi  Rr, Ir K527N R463L
ICC107 New Delhi  Rr, Or, Sr N518T, R528P S95T NM
ICC109 New Delhi  Ir NM
ICC111 New Delhi  Rr, Ir, Sr S531W Insertion 185C K121K
ICC114 New Delhi  Ir R463L
ICC115 New Delhi  Rr, Ir S531W Insertion 98A, R463L
ICC123 New Delhi  Rr, Ir, Or R528P NA S95T
ICC124 New Delhi  Rr, Ir H526Y R463L
ICC125 New Delhi  Rr L511L, S531L
ICC128 New Delhi  Rr, Or, Sr H526Y, R528H S95T K121K
ICC129 New Delhi  Rr, Ir, Sr R528P R463L K121K
ICC147 New Delhi  Rr, Ir, Or S531W 109G, R463L S95T
ICC203 New Delhi  Rr D516V
ICC204 New Delhi  Rr, Ir L521L, K527N R463L
ICC205 New Delhi  Rr, Ir D516V NA
ICC206 New Delhi  Rr, Ir S531W NM
ICC208 New Delhi  Rr D516V R463L
ICC209 New Delhi  Rr D516V
ICC210 New Delhi  Rr, Or L511V, N518T S95T
ICC211 New Delhi  Ir, Or R463L S95T
ICC212 New Delhi  Rr S531L
ICC213 New Delhi  Rr, Ir R528H, S531W R463L, Inh (C/T)
ICC214 New Delhi  Ir R463L
ICC215 New Delhi  Rr S531L
ICC216 New Delhi  Rr, Sr S531L K121K
ICC217 New Delhi  Rr, Ir, Or S531L R463L S95T
ICC218 New Delhi  Rr, Ir, Or S522Q R463L S95T
ICC219 New Delhi  Ir T12P, R463L
ICC220 New Delhi  Rr, Ir, Or, Sr S531W R463L, Inh (T/A) D94G, S95T NM
ICC221 New Delhi  Rr, Or L521L D94A, S95T
ICC222 New Delhi  Or S95T
ICC223 New Delhi  Rr, Or H526Y S95T
ICC225 New Delhi  Rr, Or S531L S95T
ICC237 New Delhi  Rr, Or D516G S95T
ICC239 New Delhi  Rr, Ir D516V R463L
ICC240 New Delhi  Rr, Ir D516V R463L
ICC242 New Delhi  Rr, Or L511V S95T
ICC244 New Delhi  Rr, Ir, Or S531L A61T, R463L S95T
ICC246 New Delhi  Ir, Or Insertion 185C, R463L S95T
ICC275 New Delhi  Rr, Or H526Y S95T
ICC277 New Delhi  Rr, Ir, Or, Sr H526Y 30C D94A, S95T K121K
ICC284 New Delhi  Or NM
ICC286 New Delhi  Rr, Ir D516G NM
ICC287 New Delhi  Rr, Ir H526Y NM
ICC325 New Delhi  Ir, Or, Sr NM NM NM
ICC326 New Delhi  Rr, Ir, Sr H526L Insertion 98A, R463L NM
ICC327 New Delhi  Rr, Ir, Sr S509R R463L K121K
ICC328 New Delhi  Or NM
ICC408 New Delhi  Rr, Ir, Or, Sr Q510H, S531W R463L S95T K121K
ICC425 New Delhi  Rr, Ir S531L R463L
F4 New Delhi  Rr, Or H526Y D94G, S95T
F5 New Delhi  Rr, Or S531L S95T
F7 New Delhi  Rr, Or S531L A90V, S95T
F8 New Delhi  Rr, Or S531L A90V, S95T
F9 New Delhi  Rr, Or N518T S91P, S95T
N31 New Delhi  Ir R463L
Continued on following page
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TABLE 2—Continued
Strain no. Geographiclocation
Treatment
historya
Drug
susceptibilityb
Polymorphismc
rpo katG or inhA gyrA rpsL
N33 New Delhi  Ir R463L
N34 New Delhi  Ir R463L
N35 New Delhi  Ir D73N, R463L
N36 New Delhi  Ir R463L
ICC32 Ahmedabad  Rr, Ir S531L NA
ICC33 Ahmedabad  Rr, Ir, Or S509R R463L S95T
ICC36 Ahmedabad  Ir, Or R463L S95T
ICC37 Ahmedabad  Rr, Ir D516G Insertion 98A, R463L
ICC131 Ahmedabad  Rr, Ir H526Y, R528P R463L
ICC132 Ahmedabad  Or S95T
ICC133 Ahmedabad  Rr, Ir H526R 30C, R463L
ICC134 Ahmedabad  Rr, Or S522Q S95T
ICC136 Ahmedabad  Rr, Ir H526R Insertion 98A, R463L
ICC137 Ahmedabad  Or S95T
ICC138 Ahmedabad  Or S95T
ICC226 Ahmedabad  Rr, Ir L511L, H526R 109G, R463L
ICC233 Ahmedabad  Rr, Ir D516V, H526Y 30C, R463L
ICC151 Chandigarh  Or S95T
ICC154 Chandigarh  Rr, Ir, Or S531L 30C, R463L S95T
ICC155 Chandigarh  Ir 30C, R463L
ICC159 Chandigarh  Rr, Or H526Y S95T
ICC161 Chandigarh  Rr, Or S522Q S95T
ICC162 Chandigarh  Rr, Or S522Q S95T
ICC164 Chandigarh  Or S95T
ICC165 Chandigarh  Or S95T
ICC166 Chandigarh  Or S95T
ICC167 Chandigarh  Ir, Or R463L S95T
ICC168 Chandigarh  Or S95T
ICC169 Chandigarh  Rr, Ir N518T R463L
ICC170 Chandigarh  Or S95T
ICC171 Chandigarh  Rr, Ir S531L R463L
ICC172 Chandigarh  Rr, Or S522Q S95T
ICC173 Chandigarh  Rr, Sr H526L K121K
ICC174 Chandigarh  Or S95T
ICC175 Chandigarh  Rr, Or H526Y S95T
ICC247 Chandigarh  Rr, Or D516V S95T
ICC248 Chandigarh  Rr, Or D516V S95T
ICC249 Chandigarh  Or S95T
ICC251 Chandigarh  Or NM
ICC254 Chandigarh  Rr S531L
ICC255 Chandigarh  Rr, Or N518T NM
ICC256 Chandigarh  Rr, Ir H526Y NM
ICC257 Chandigarh  Rr, Or Q510H, L511L S95T
ICC262 Chandigarh  Rr, Ir, Or D516V R463L S95T
ICC95 Bangalore  Or S95T
ICC96 Bangalore  Rr, Or S531L S95T
ICC399 Bangalore  Rr, Or S531W NM
ICC524 Bangalore  Rr, Ir S531L R463L
ICC525 Bangalore  Rr, Ir S531L R463L
ICC143 Shimla  Or NM
ICC144 Shimla  Ir R463L
ICC145 Shimla  Or NM
A3 Agra  Rr, Ir, Sr S531L R463L NM
A4 Agra  Rr, Ir D516V R463L
A9 Agra  Rr, Ir S531L R463L
A11 Agra  Rr, Ir D516G T11A, R463L
A12 Agra  Rr, Ir D516V N35D, R463L
A13 Agra  Rr, Ir D516V, N518T R463L
A14 Agra  Rr, Ir D516V R463L
A15 Agra  Rr, Ir S531L R463L
ICC332 Jaipur  Rr, Ir H526R Insertion 185C, R463L
ICC337 Jaipur  Rr, Ir S531L R463L S95T
ICC85 Chennai  Rr, Ir, Or H526R NA S95T
a History of treatment in the previous 20 months.
b Rr, rifampin resistant; Ir, isoniazid resistant; Or, ofloxacin resistant; Sr, streptomycin resistant.
c NA, no amplification; NM, no mutation; Inh, mutation in the inhA ribosome binding site; , deletion at the indicated nucleotide position.
446 SIDDIQI ET AL. ANTIMICROB. AGENTS CHEMOTHER.
were recovered. These isolates probably represent those with
acquired resistance, as the patients had at some time point
been given antitubercular drug therapy.
A stretch of 30 amino acids at the center of the amplicon for
the rpoB locus was studied. Amino acids 432 to 458 comprised
the hot-spot region for mutations. For the sake of comparison,
we used the corresponding Escherichia coli numbering, which
is amino acids 507 to 533. We identified previously reported
mutations as well as certain novel mutations. Codon 531
seemed to be the most vulnerable to mutations, as most ri-
fampin-resistant isolates had this mutation (Fig. 1). Of the 93
rifampin-resistant strains in our study, 28 had the missense
mutation Ser531Leu and 8 had the substitution Ser531Trp.
The next most common mutations were the amino acid sub-
stitutions Asp516Val or Asp516Gly (20 isolates) and
His526Tyr, His526Leu, or His526Arg (19 isolates). We found
two isolates with Gln510His changes. While all these mutations
have been reported earlier, we also found mutations that have
not been reported previously. These included Ser509Arg (iso-
late ICC33), Leu511Val (isolate ICC242), Asn518Thr (isolate
ICC107), Ser522Gln (isolate ICC172), Lys527Asn (isolate
ICC105), Arg528Pro (isolate ICC129), and Arg528His (isolate
ICC213). Most of these mutations occurred less frequently,
comprising about 24% of the total mutations in the 94 isolates
studied. Other mutations identified in our study were silent
mutations at amino acids Leu511 and Leu521. Interestingly,
the mutation at position 511 never occurred alone and was
present only in isolates with more than one mutation at the
rpoB locus.
An important outcome of these studies is the direct corre-
lation of certain mutations to high MICs. Table 3 lists the
isolates, their mutations, and the corresponding MICs at which
they remained resistant. Mutations in codons 516 and 521
conferred low-level resistance (MIC, 40 g/ml) to rifampin,
whereas mutations in codons 510, 526, 527, 528, and 531 were
seen to confer high levels of resistance (MICs, 64 g/ml).
Amino acids 526 to 531 appear to be very important in drug
target interactions, and mutations in them result in MICs in
the range of 64 g/ml and above. In a few cases (e.g., for
isolates ICC204, ICC257, and ICC128), double mutations were
found to have an additive effect on the degree of resistance.
Insertion, deletion, and substitution mutations were mapped
in the katG locus in 24 isoniazid-resistant isolates. In the
present study we looked for mutations in the 5 region (nucle-
otides [nt] 3 to 239) and the midregion (nt 1187 to 1600) of the
katG gene, corresponding to amino acid positions 2 to 77 and
395 to 533, respectively. The results are summarized in Fig. 2.
A C nucleotide at position 30 was deleted in six of the isolates.
This deletion results in chain termination, thereby generating
only a short polypeptide of 26 amino acids. Another deletion of
a single nucleotide, a G residue at position 109, was observed
in two isolates; this deletion would result in the production of
FIG. 1. Summary of mutations at codons 508 to 532 in the rpoB gene. The wild-type sequence and amino acids are shown in the middle frame.
Nucleotide changes are marked with arrows in the top frame, and the corresponding amino acid changes are denoted in the bottom frame. The
amino acids are subscripted with numbers that indicate the number of isolates harboring the change. Changes marked with orange lines (dotted
arrows) are novel mutations; silent mutations are marked with blue lines (dashed arrows). Codons 531, 526, and 516 exhibit high degrees of
polymorphism. Codons 509, 511, 522, 527, and 528 show novel mutations.
TABLE 3. Correlation of specific mutations with rifampin MICsa
Strain Rifampin MIC(g/ml) Mutation
Mutation
type
Amino acid
change
ICC221 10 G1317A Novel L521L
ICC208, ICC205 10 A1304T Reported D516V
ICC37 10 A1304G Reported D516G
ICC204 40 G1317A Novel L521L
ICC204 40 G1336T Novel K527N
ICC105 40 G1336T Novel K527N
ICC129 40 G1338C Novel R528P
ICC131 40 C1331T Reported H526Y
ICC131 40 G1338C Novel R528P
ICC123 64 G1338C Novel R528P
ICC100 64 C1349T Reported S531L
ICC213 64 G1340A Novel R528H
ICC213 64 C1349G Reported S531W
ICC218 64 T1321C Novel S522Q
ICC218 64 C1322A Novel S522Q
ICC257 64 G1287T Novel Q510H
ICC257 64 C1288T Novel L511L
ICC275 64 C1333T Reported H526Y
ICC220 64 C1349G Reported S531W
ICC128 128 C1331T Reported H526Y
ICC128 128 G1338A Novel R528H
a Missense mutations in the RpoB protein at amino acid positions 510, 511,
522, 526, 527, 528, and 531 confer higher levels of resistance (MICs, 40 g/ml)
than those at positions 509, 516, and 521 (MICs, 10 g/ml).
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a 45-amino-acid truncated polypeptide. Insertions were also
observed at nt positions 98 (an A nucleotide) and 185 (a C
nucleotide) in four and three isolates, respectively. Both of
these insertions cause aberrant chain termination. Ala61Thr,
Thr12Pro, Thr11Ala, Asp73Asn, and Asn35Asp missense mu-
tations were observed in this locus in a few of the isolates.
These are novel observations, as there are no reports of such
mutations occurring in isoniazid-resistant strains from other
parts of the world. We were unable to amplify this locus in six
of the isolates (isolates ICC14, ICC23, ICC32, ICC85, ICC123,
and ICC205), indicating a partial deletion of the gene. A com-
mon mutation in all these isolates was Arg463Leu. However,
this mutation has been shown to have no direct consequence
for drug resistance. To confirm this we sequenced this locus for
all 126 isolates included in the study. It was found that the
majority of the isolates carried this change. It has been argued
previously that this polymorphism in the katG locus might be
more important as a marker of evolution than as a marker of
resistance (22). Three isoniazid-resistant isolates carried mu-
tations in the ribosomal binding site upstream of the inhA
gene. While two isolates showed a C-to-T transition, one had a
T-to-A transversion. These mutations have previously been
reported by other groups. The present understanding of these
mutations is that they probably confer resistance by a drug
titration effect.
Sixty-eight ofloxacin-resistant isolates were analyzed. The
hot-spot region of the gyrA gene spanning codons 89 to 95 was
sequenced to identify mutations. Most of the isolates showed a
single mutation corresponding to the amino acid change
Ser95Thr (Fig. 3). The second most common mutation, ob-
served in four isolates, was Asp94Gly or Asp94Ala. Two iso-
lates had an Ala90Val substitution, while one had a silent
mutation at this codon. Seven isolates had double mutations,
with the S95T change being common to all seven. These mu-
tations were present in MDR isolates for which the MICs of
the drugs were high, including the frontline drugs used in
antituberculosis therapy. All strains were also checked for mu-
tations in the gyrB locus, which is associated with low levels of
resistance. However, we found no mutations in the gyrB loci of
these isolates. It has been argued that the S95T mutation does
not correlate with drug resistance (22). It therefore appears
that the isolates have acquired resistance to ofloxacin via other
mechanisms.
We tested 14 isolates resistant to streptomycin for mutations
in the rpsL and rrs loci. In eight strains we found a novel silent
mutation at amino acid position 121 in the rpsL locus, where
the codon AAA (Lys) was changed to AAG (Lys), but we
found no mutations in the rrs genes. To our knowledge, there
are no reports of this mutation. The reported mutations at the
rpsL locus are generally Leu43Arg, Leu43Thr, or Lys88Arg.
We are still not clear about how a mutation at this locus leads
to the development of streptomycin resistance. The remaining
isolates probably acquired resistance by other means, such as
by the development of a permeability barrier or by the pro-
duction of drug-altering enzymes.
A point to be kept in mind is that the majority of isolates
included in the present study were from North India. Our data
are therefore inherently biased toward drug-resistant strains
from this region and should not be seen as representative for
isolates from the whole of India.
DISCUSSION
The mycobacterium uses various mechanisms to evade kill-
ing by drugs, including mutations in genes that code for drug
target proteins (20), a complex cell wall which blocks drug
entry, and membrane proteins that act as drug efflux pumps (6,
14). The objective of the present study was to identify muta-
FIG. 2. Summary of mutations in the katG gene. Deletions are indicated by lines with a minus sign, while insertions are depicted by dashed lines
with a plus sign. Solid lines show the substitutions. Codon 463 exhibited the highest degree of polymorphism, followed by the deletion at nucleotide 30.
FIG. 3. Summary of missense mutations in the gyrA locus. Nucleotide changes are indicated on top of the wild-type sequence, and the
corresponding amino acid changes are shown at the bottom. The most common mutation in this locus is Ser95Thr.
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tions in drug target loci in Indian strains of M. tuberculosis and
to identify the different drug resistance genotypes. As in all
such studies, the aim was to generate information about the
markers associated with drug resistance, polymorphisms in the
drug target genes, the association of the level of resistance with
particular mutations, etc. Our findings of mutations in the
rpoB, katG, and rpsL loci are similar to those reported from
other parts of the world, especially the common mutations,
which reflect a global pattern (20). Rifampin resistance is often
regarded as an excellent surrogate marker for MDR tubercu-
losis (4, 10), and our study corroborates this hypothesis. The
mutation frequency of codon 531 (rpoB) was similar to that
reported earlier (13, 17, 19, 20, 21, 25). Significantly, the fre-
quency of mutations (relative to those of other mutations) was
higher at codon 516 and lower at codon 526 in Indian isolates
compared to those reported elsewhere. We found novel mu-
tations that broaden the range of known mutations at this
locus. When taken together, these mutations were detected in
a significant number of drug-resistant isolates, a fact that needs
to be considered when designing tools for the detection of
MDR M. tuberculosis. We found a definite correlation between
MICs and the type of mutation in many isolates. As reported
by previous investigators (24), mutations at positions 528 and
531 are important in the development of high MICs. Our
findings further strengthen the belief that the degree of resis-
tance to rifampin exhibited by an isolate is related to the type
of mutation in the rpoB locus.
In isoniazid-resistant isolates, significantly more deletion
and insertion mutations than substitution mutations were
found, of which a few have been reported previously (11, 19).
We observed that almost all isolates studied carried the
Arg463Leu substitution, which is also present in isolates that
were sensitive to isoniazid. This is in concordance with a report
from Sreevatsan et al. (22), who argue that polymorphism at
this residue does not contribute to resistance per se but is an
important marker for evolutionary genetics. The insertions and
deletions in the katG locus invariably resulted in chain trun-
cation and termination, leading to the generation of dysfunc-
tional polypeptides. We found changes in the putative ribo-
somal binding site of the inhA gene in three isolates. While the
exact mechanism of how these mutations confer resistance to
isoniazid is not clear, reports (1, 18, 20) indicate that they
probably increase the levels of enoyl-acyl carrier protein re-
ductase which in turn leads to resistance via a drug titration
mechanism. In isolates with no mutations in the hot-spot re-
gion of the gene, the complete sequencing of the gene is being
done. However, resistance to isoniazid can also be due to
mutations in the ahpC-oxyR and kasA gene loci (7, 16).
Fluoroquinolones comprise the secondary drug regimen in
the treatment of tuberculosis. A large number of isolates were
resistant to ofloxacin, which could be due in part to the inac-
curate diagnosis of tuberculosis as a bacterial infection and
fluoroquinolone overuse in the population. Codons 89, 90, 91,
94, and 95 in the gyrA gene have been shown to be polymorphic
(20, 23, 26). The most common mutation in ofloxacin-resistant
isolates in the present study was Ser95Thr, which reportedly
has no direct role in the development of drug resistance, as it
also occurs in drug-sensitive strains (22). It seems likely that
ofloxacin resistance possibly results due to mutations else-
where in the gene or the presence of drug efflux pumps.
Mutations in codons 43 and 88 of the rpsL gene generally
result in high levels of resistance to streptomycin, while muta-
tions in the loop at codon 530 or the region at codon 915 of the
rrs locus are associated with low levels of resistance (3). We did
not find any of these mutations in the 14 streptomycin-resistant
isolates included in our study. However, we did observe a silent
mutation at codon 121 that has not been reported by any other
group.
Our study provides valuable data on the different kinds of
mutations occurring at various target loci in Indian clinical
isolates of M. tuberculosis that enhance our understanding of
the molecular mechanisms of drug resistance. The diversity of
the polymorphisms exhibited at these loci by the drug-resistant
strains indicates the prevalence of a large numbers of drug-
resistant strains in this region. Additionally, our data will also
assist in the process of designing new molecular biology-based
techniques for the diagnosis of MDR tuberculosis. Such meth-
ods promise faster detection rates compared to those achieved
by methods based solely on culture of the isolates.
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